// App-Quantinova.ai

e15099 : Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma.

Researchers

Presenter

  • Melissa A. Eastgate

Principal Investigators

  • Victoria Atkinson

  • Muhammad Adnan Khattak

  • Amitesh Chandra Roy

  • Andrew Mark Haydon

  • Christian Mueller

  • Tina Dunkelmann

  • Chrystelle Brignone

  • Frederic Triebel

Medical Centers

  • Royal Brisbane and Women's Hospital, Herston, Australia

  • The University of Queensland, Brisbane, Australia

  • Fiona Stanley Hospital/ University of Western Australia, Perth, Australia

  • Flinders University Medical Centre, Adelaide, Australia

  • The Alfred Hospital, Melbourne, Australia

  • Clinical Development, Immutep, Berlin, Germany

  • Immutep Limited, Berlin, Germany

  • Research & Development, Immutep, Paris, France

Locations

  • France

  • Germany

  • Australia

Companies

  • Immutep Ltd

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • EDP 202

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02676869

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved